<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0502256827
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAMUCON 500 mg F.C.TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MYCOPHENOLATE MOFETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        158.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sandoz Private Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sandoz Private Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            HEXAL AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA06 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lamucon contains mycophenolate mofetil. This belongs to a group of medicines called &ldquo;<strong>immunosuppressants&rdquo;.</strong></p><p>Lamucon is used to prevent your body rejecting a transplanted organ:</p><ul><li>A kidney, heart or liver.</li></ul><p>Lamucon should be used together with other medicines:</p><ul><li>&nbsp;Ciclosporin and corticosteroids.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>WARNING</p><p>Mycophenolate causes birth defects and miscarriage. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor.</p><p>&nbsp;</p><p>Your doctor will speak to you and give you written information, particularly on the effects of mycophenolate on unborn babies. Read the information carefully and follow the instructions.</p><p>&nbsp;</p><p>If you do not fully understand these instructions, please ask your doctor to explain them again before you take mycophenolate. See also further information in this section under &ldquo;Warnings and precautions&rdquo; and &ldquo;Pregnancy and breast-feeding&rdquo;.</p><p><strong>&nbsp;</strong></p><p><strong>Do not take Lamucon :</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to mycophenolate mofetil, mycophenolic acid or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription as mycophenolate causes birth defects and miscarriage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or planning to become pregnant or think you may be pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are not using effective contraception (see Pregnancy, contraception and breast-feeding).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding.</p><p>Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Lamucon .</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor straight away before taking Lamucon :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a sign of infection such as a fever or sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any unexpected bruising or bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a problem with your digestive system such as a &nbsp;stomach ulcer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are planning to become pregnant, or if you get pregnant while you or your partner are taking Lamucon .</p><p>If any of the above apply to you (or you are not sure), talk to your doctor straight away before taking Lamucon .</p><p>&nbsp;</p><p><strong>The effect of sunlight</strong></p><p>Lamucon reduces your body&rsquo;s defences. As a result, there is an increased risk of skin cancer. Limit the amount of sunlight and UV light you get. Do this by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wearing protective clothing that also covers your head, neck, arms and legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; using a sunscreen with a high protection factor.</p><p>&nbsp;</p><p><strong>Other medicines and Lamucon </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because Lamucon can affect the way some other medicines work. Also other medicines can affect the way Lamucon works. In particular, tell your doctor or pharmacist if you are taking any of the following medicines before you start Lamucon :</p><p>&nbsp;</p><ul><li>azathioprine or other medicines that suppress your immune system &ndash; given after a transplant operation</li><li>cholestyramine &ndash; used to treat high cholesterol</li><li>rifampicin &ndash; an antibiotic used to prevent and treat infections such as tuberculosis (TB)</li><li>antacids or proton pump inhibitors &ndash; used for acid problems in your stomach such as indigestion</li><li>phosphate binders &ndash; used by people with chronic kidney failure to reduce how much phosphate gets absorbed into their blood.</li><li>antibiotics - used to treat bacterial infections</li><li>isavuconazole &ndash; used to treat fungal infections</li><li>telmisartan - used to treat high blood pressure</li></ul><p>&nbsp;</p><p><strong>Vaccines</strong></p><p>If you need to have a vaccine (a live vaccine) while taking Lamucon , talk to your doctor or pharmacist first. Your doctor will have to advise you on what vaccines you can have.</p><p>&nbsp;</p><p>You must not donate blood during treatment with Lamucon and for at least 6 weeks after stopping treatment. Men must not donate semen during treatment with Lamucon and for at least 90 days after stopping treatment.</p><p>&nbsp;</p><p>Lamucon <strong>with food and drink</strong></p><p>Taking food and drink has no effect on your treatment with Lamucon .</p><p>&nbsp;</p><p><strong>Pregnancy, contraception and breast-feeding</strong></p><p>&nbsp;</p><p><strong>Contraception in women taking Lamucon </strong></p><p>If you are a woman who could become pregnant you must use an effective method of contraception with Lamucon . This includes:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you start taking Lamucon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During your entire treatment with Lamucon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For 6 weeks after you stop taking Lamucon</p><p>&nbsp;</p><p>Talk to your doctor about the most suitable contraception for you. This will depend on your individual situation. Two forms of contraception are preferable as this will reduce the risk of unintended pregnancy. &nbsp;<strong>Contact your doctor as soon as possible, if you think your contraception may not have been effective or if you have forgotten to take your contraceptive pill.</strong></p><p>&nbsp;</p><p>You are a woman who is not capable of becoming pregnant if any of the following applies to you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have had treatment for cancer, then there is still a chance you could become pregnant).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your fallopian tubes and both ovaries have been removed by surgery (bilateral salpingo-oophorectomy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your womb (uterus) has been removed by surgery (hysterectomy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your ovaries no longer work (premature ovarian failure which has been confirmed by a specialist gynaecologist).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner&rsquo;s syndrome or uterine agenesis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are a child or teenager who has not started having periods.</p><p><strong>&nbsp;</strong></p><p><strong>Contraception in men taking </strong>Lamucon</p><p>The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. However, a risk cannot be completely excluded. As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking Lamucon .</p><p>If you are planning to have a child, talk to your doctor about the potential risks and alternative therapies.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will talk to you about the risks in case of pregnancy and the alternatives you can take to prevent rejection of your transplant organ if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You plan to become pregnant.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You miss or think you have missed a period, or you have unusual menstrual bleeding, or suspect you are pregnant.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have sex without using an effective method of contraception.</p><p>If you do become pregnant during the treatment with mycophenolate, you must inform your doctor immediately. However, keep taking Lamucon until you see him or her.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>Mycophenolate causes a very high frequency of miscarriage (50%) and of severe birth defects (23-27 %) in the unborn baby. Birth defects that have been reported include anomalies of ears, of eyes, of face (cleft lip/palate), of development of fingers, of heart, oesophagus (tube that connects the throat with the stomach), kidneys and nervous system (for example spina bifida (where the bones of the spine are not properly developed)). Your baby may be affected by one or more of these.</p><p>&nbsp;</p><p>If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor may request more than one test to ensure you are not pregnant before starting treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Breast-feeding</strong></p><p>Do not take Lamucon if you are breast-feeding. This is because small amounts of the medicine can pass into the mother&rsquo;s milk.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Mycophenolate mofetil has a moderate influence on your ability to drive or use any tools or machines. If you feel drowsy, numb or confused, talk to your doctor or nurse and do not drive or use any tools or machines until you feel better.</p><p><strong>&nbsp;</strong></p><p><strong>Lamucon contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine<strong> </strong>exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The amount you take depends on the type of transplant you have had. The usual doses are shown below. Treatment will continue for as long as you need to prevent you from rejecting your transplant organ.</p><p>&nbsp;</p><p><strong>Kidney transplant</strong></p><p>Adults</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first dose is given within 3 days of the transplant operation.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take 2 tablets in the morning and then 2 tablets in the evening.</p><p>Children (aged 2 to 18 years)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose given will vary depending on the size of the child.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide the most appropriate dose based on your child&rsquo;s height and weight (body surface area measured as square metres or &ldquo;m<sup>2</sup>&rdquo;). The recommended dose is 600 mg/m<sup>2</sup> taken twice a day.</p><p><em>&nbsp;</em></p><p><em>Use in special populations</em></p><p>&nbsp;</p><p>Elderly</p><p>The recommended dose of 1 g administered twice a day for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly.</p><p>&nbsp;</p><p><strong>Heart transplant</strong></p><p>Adults</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The first dose is given within 5 days of the transplant operation.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take 3 tablets in the morning and then 3 tablets in the evening.</p><p>Children</p><p>There is no information for the use of mycophenolate mofetil in children with a heart transplant.</p><p>&nbsp;</p><p><strong>Liver transplant</strong></p><p>Adults</p><ul><li>The first dose of oral mycophenolate mofetil will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines.</li><li>The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses.</li><li>Take 3 tablets in the morning and then 3 tablets in the evening.</li></ul><p>Children</p><p>There is no information for the use of Lamucon in children with a liver transplant.</p><p>&nbsp;</p><p><strong>Taking the medicine</strong></p><ul><li>Swallow your tablets whole with a glass of water.</li><li>Do not break or crush them.</li></ul><p>&nbsp;</p><p><strong>If you take more Lamucon than you should</strong></p><p>If you take more of this medicine than you should, talk to a doctor or go to a hospital straight away. Also do this if someone else accidentaly takes your medicine. Take the medicine pack with you.</p><p>&nbsp;</p><p><strong>If you forget to take Lamucon </strong></p><p>If you forget to take your medicine at any time, take it as soon as you remember. Then continue to take it at the usual times. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Lamucon </strong></p><p>Do not stop taking this medicine unless your doctor tells you to. If you stop your treatment you may increase the chance of rejection of your transplant organ.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Talk to a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a sign of infection such as a fever or sore throat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any unexpected bruising or bleeding</p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>you have a rash, swelling of your face, lips, tongue or throat, with difficulty breathing - you may be having a serious allergic reaction to the medicine <strong>(such as anaphylaxis, </strong>angioeodema<strong>).</strong></p><p>&nbsp;</p><p><strong>Usual problems</strong></p><p>Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting. Your doctor will do regular blood tests to check for any changes in:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the number of your blood cells or signs of infections.</p><p>&nbsp;</p><p>Children may be more likely than adults to have some side effects. These include diarrhoea, infections, fewer white cells and fewer red cells in the blood.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fighting infections </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lamucon </strong>reduces your body&rsquo;s defences. This is to stop you rejecting your transplant. As a result, your body will not be as good as normal at fighting infections. This means you may catch more infections than usual. This includes infections of the brain, skin, mouth, stomach and gut, lungs and urinary system.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lymph and skin cancer </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As can happen in patients taking this type of medicine (immune-suppressants), a very small number of <strong>Lamucon </strong>patients have developed cancer of the lymphoid tissues and skin.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>General unwanted effects </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may get general side effects affecting your body as a whole. These include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty sleeping, pains (such as stomach, chest, joint or muscle), headache, flu symptoms and swelling.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other unwanted effects may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin problems </strong>such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne, cold sores, shingles, skin growth, hair loss, rash, itching.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Urinary problems </strong>such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in the urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digestive system and mouth problems </strong>such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the gums and mouth ulcers,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas, colon or stomach,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal disorders including bleeding,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disorders,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, constipation, feeling sick (nausea), indigestion, loss of appetite, flatulence.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system problems </strong>such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, drowsy or numb,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor, muscle spasms, convulsions,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious or depressed, changes in your mood or thoughts.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and blood vessel problems </strong>such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in blood pressure, accelerated heartbeat, widening of blood vessels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lung problems </strong>such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia, bronchitis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, cough, which can be due to bronchiectasis (a condition in which the lung airways are abnormally dilated) or pulmonary fibrosis (scarring of the lung). Talk to your doctor if you develop a persistent cough or breathlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluid on the lungs or inside the chest,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sinus problems.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other problems </strong>such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss, gout, high blood sugar, bleeding, bruising.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s)</p><ul><li>Saudi Arabia</li></ul><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_16" o:spid="_x0000_s1028"
 type="#_x0000_t202" style='position:absolute;margin-left:0;margin-top:11.3pt;
 width:429pt;height:104.9pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:left;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
    style='mso-spacerun:yes'> </span>NPC contact information Saudi Arabia:<o:p></o:p></span></b></p>
    <p class=MsoPlainText><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo7'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif'>The National Pharmacovigilance
    Centre (NPC):<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo7'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif'>SFDA Call Center: 19999<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo7'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:11.0pt;
    font-family:"Times New Roman",serif;color:windowtext;text-decoration:none;
    text-underline:none'>npc.drug@sfda.gov.sa</span></a><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif'><o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l1 level1 lfo7'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif'>Website ade.sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;margin-left:.3pt;margin-top:133.35pt;width:429pt;
 height:89.25pt;z-index:251661312;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:2.0pt;margin-right:0in;margin-bottom:
    2.0pt;margin-left:0in;mso-add-space:auto;line-height:12.6pt;text-autospace:
    none'><b><span style='font-size:11.0pt'>Patient Safety Department Novartis
    Consulting AG - Saudi Arabia:<o:p></o:p></span></b></p>
    <p class=MsoListParagraphCxSpFirst style='margin-top:2.0pt;margin-right:
    0in;margin-bottom:2.0pt;margin-left:.25in;mso-add-space:auto;text-indent:
    -.25in;line-height:12.6pt;mso-list:l4 level1 lfo6;text-autospace:none'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-fareast-language:EN-US'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='mso-bidi-font-size:11.0pt;mso-fareast-language:
    EN-US'>Toll Free Number: 8001240078<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-top:2.0pt;margin-right:
    0in;margin-bottom:2.0pt;margin-left:.25in;mso-add-space:auto;text-indent:
    -.25in;line-height:12.6pt;mso-list:l4 level1 lfo6;text-autospace:none'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-fareast-language:EN-US'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='mso-bidi-font-size:11.0pt;mso-fareast-language:
    EN-US'>Phone: +966112658100<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-top:2.0pt;margin-right:
    0in;margin-bottom:2.0pt;margin-left:.25in;mso-add-space:auto;text-indent:
    -.25in;line-height:12.6pt;mso-list:l4 level1 lfo6;text-autospace:none'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-fareast-language:EN-US'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='mso-bidi-font-size:11.0pt;mso-fareast-language:
    EN-US'>Fax: +966112658107<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast style='margin-left:.25in;mso-add-space:
    auto;text-indent:-.25in;mso-list:l4 level1 lfo6;text-autospace:none'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";mso-fareast-language:EN-US'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='mso-bidi-font-size:11.0pt;mso-fareast-language:
    EN-US'>Email:&nbsp;adverse.events@novartis.com<o:p></o:p></span></p>
    <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="146" alt="Text Box:  NPC contact information Saudi Arabia:

o	The National Pharmacovigilance Centre (NPC):
o	SFDA Call Center: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="125" alt="Text Box: Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o	Toll Free Number: 8001240078
o	Phone: +966112658100
o	Fax: +966112658107
o	Email: adverse.events@novartis.com

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><ul><br /><li><strong>Other GCC states</strong></li><li><!--[if gte vml 1]><v:shape
      id="Text_x0020_Box_x0020_15" o:spid="_x0000_s1026" type="#_x0000_t202"
      style='position:absolute;left:0;text-align:left;margin-left:0;
      margin-top:3.5pt;width:429pt;height:23.25pt;text-indent:0;z-index:251660288;
      visibility:visible;mso-wrap-style:square;mso-width-percent:0;
      mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
      mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
      mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
      mso-position-vertical:absolute;mso-position-vertical-relative:text;
      mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
      mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
      <v:path arrowok="t"/>
      <v:textbox>
       <![if !mso]>
       <table cellpadding=0 cellspacing=0 width="100%">
        <tr>
         <td><![endif]>
         <div>
         <p class=MsoListParagraph style='text-indent:-.25in;mso-list:l5 level1 lfo5;
         mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
         style='font-size:12.0pt;mso-bidi-font-size:11.0pt;mso-fareast-language:
         EN-US'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         </span></span></span><![endif]><span dir=LTR></span><span
         style='mso-bidi-font-size:11.0pt;mso-fareast-language:EN-US'>Please
         contact the relevant competent authority. <o:p></o:p></span></p>
         <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
         mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
         <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
         mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
         </div>
         <![if !mso]></td>
        </tr>
       </table>
       <![endif]></v:textbox>
      <w:wrap anchorx="margin"/>
     </v:shape><![endif]--><img width="578" height="37" alt="Text Box: -	Please contact the relevant competent authority. 


" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image003.gif" />&nbsp;</li></ul><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton, blister or the label after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is mycophenolate mofetil. Each film-coated tablet contains 500 mg of mycophenolate mofetil.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Core content:</p><p>Cellulose microcrystalline, Povidone, Talc, Magnesium stearate, Croscarmellose sodium.</p><p>&nbsp;</p><p>Coating content:</p><p>Hypromellose, Hydroxypropylcellulose, Titanium dioxide (E171), Macrogol (400); Iron oxide black (E172), Iron oxide red (E172)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lamucon film-coated tablets are lavender coloured, film coated biconvex tablet plain on both the sides.
PVC/PE/PVdC/Al blister
Pack sizes: 50, film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder</strong></p><p>HEXAL AG</p><p>Industriestrasse 25, 83607</p><p>Holzkirchen, Germany</p><p><strong>Manufacturer</strong></p><p>Sandoz Private Limited</p><p>Mumbai, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار لاموكون على مَيكوفينوليت موفيتيل. ينتمي هذا الدَّواء إلى مجموعة من الأدوية تسمى <strong>&quot;كابتات المناعة&quot;.</strong></p><p dir="RTL">يُستَخدَم عقار لاموكون للحيلولة دون رفض الجسم للأعضاء المزروعة مثل:</p><ul><li dir="RTL">الكلية أو القلب أو الكبد.</li></ul><p dir="RTL">يجب استخدام عقار لاموكون بمصاحبة أدوية أخرى مثل:</p><ul><li dir="RTL">&nbsp;سيكلوسبورين والكورتيكوستيرويدات.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحذير:</p><p dir="RTL">يُسبب مَيكوفينوليت العيوب الخلقية والإجهاض. إذا كنتِ سيدة قادرة على الحمل، يجب عليكِ تقديم اختبار حمل سلبي قبل بدء العلاج ويجب عليكِ اتباع النصيحة التي يُقدمها لك طبيبكِ بخصوص منع الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتحدث طبيبكِ معكِ وسيقدم لك معلومات مكتوبة، وبالتحديد حول تأثيرات مَيكوفينوليت على الأجنة. يُرجى قراءة المعلومات بعناية واتباع التعليمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تفهمي هذه التعليمات فهمًا تامًّا، فيرجى أن تطلبي من طبيبكِ شرحها مرة أخرى قبل أن تتناولي مَيكوفينوليت. اطلعي أيضًا على مزيد من المعلومات في هذا القسم تحت عنوان &quot;تحذيرات واحتياطات&quot; و&quot;الحمل والرضاعة الطبيعية&quot;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تتناول عقار لاموكون في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية (فرط الحساسية) تجاه مَيكوفينوليت موفيتيل أو حمض المَيكوفينوليك، أو تجاه أيٍّ من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ سيدة يمكنها الحمل ولم تقدمي اختبار حملٍ نتيجته سلبية قبل الوصفة الطبية الأولى لكِ؛ لأن مَيكوفينوليت يسبب العيوب الخلقية والإجهاض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تخططين لذلك أو تعتقدين أنكِ قد تكونين حاملًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ لا تستخدمين وسائل منع حمل فعالة (انظري قسم الحمل، ومنع الحمل، والرضاعة الطبيعية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا.</p><p dir="RTL">لا تتناول هذا الدواء إذا كان أيٌّ مما سبق ينطبق عليك. إذا لم تكن متأكدًا، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل عقار لاموكون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك فورًا قبل تناوُل عقار لاموكون في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك علامة على الإصابة بالعدوى مثل الحُمى أو التهاب الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك كدمات أو نزيف غير مُتوقعين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من مشكلة بجهازك الهضمي مثل قرحة المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تخططين للحمل أو إذا أصبحتِ حاملًا أثناء تناوُلك أو تناول شريكك عقار لاموكون.</p><p dir="RTL">إذا كان أيٌّ مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا)، تحدَّث إلى طبيبك مباشرةً قبل تناوُل عقار لاموكون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير أشعة الشمس</strong></p><p dir="RTL">يقلل عقار لاموكون من دفاعات الجسم لديك. نتيجة لذلك، توجد خطورة متزايدة للإصابة بسرطان الجلد. يجب عليك الحد من التعرض لضوء الشمس والأشعة فوق البنفسجية. قم بذلك عن طريق الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتداء ملابس واقية تغطي أيضًا رأسك وعنقك وذراعيك وساقيك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام واقٍ شمسي ذي عامل حماية مرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل أدوية أخرى مع عقار لاموكون </strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. يشمل ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية، بما في ذلك الأدوية العشبية. وذلك لأن عقار لاموكون قد يؤثر على طريقة عمل الأدوية الأخرى. قد تُؤثر الأدوية الأخرى كذلك على طريقة عمل عقار لاموكون. على وجه الخصوص، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية قبل أن تبدأ في تناوُل عقار لاموكون:</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">أزاثيوبرين أو الأدوية الأخرى الكابتة لجهازك المناعي -يتم إعطاؤها بعد عملية الزرع.</li><li dir="RTL">كولستيرامين -يُستخدم لعلاج ارتفاع الكوليسترول</li><li dir="RTL">ريفامبيسين -مضاد حيوي يُستخدَم للوقاية من العدوى مثل مرض السل وعلاجها.</li><li dir="RTL">مضادات الحموضة أو مثبطات مضخات البروتون -تُستخدم لعلاج مشاكل الحمض في المعدة مثل عسر الهضم.</li><li dir="RTL">قابضات الفوسفات -تُستخدم من قبل الأشخاص الذين يعانون منالفشل الكلوي المزمن لخفض كمية الفوسفات التي يتم امتصاصها في الدم.</li><li dir="RTL">المضادات الحيوية -تستخدم في علاج العدوى البكتيرية.</li><li dir="RTL">إيزافوكونازول -يُستخدَم لعلاج العدوى الفطرية.</li><li dir="RTL">تلميسارتان -يستخدم لعلاج ضغط الدَّم المرتفع.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اللقاحات</strong></p><p dir="RTL">إذا كنت بحاجة لتلقي لقاح (لقاح حي) أثناء تناوُل عقار لاموكون، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك أولًا. سيتعين على طبيبك تقديم المشورة لك بشأن اللقاحات التي يمكنك تلقيها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك عدم التبرع بالدَّم أثناء العلاج بعقار لاموكون ولمدة 6 أسابيع على الأقل بعد إيقاف العلاج. يجب على الرجال عدم التبرع بالمني أثناء العلاج بعقار لاموكون ولمدة 90 يومًا على الأقل بعد التوقف عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناوُل عقار لاموكون<strong> مع الأطعمة والمشروبات</strong></p><p dir="RTL">تناوُل الطعام والشراب ليس له أي تأثير على علاجك بعقار لاموكون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل، منع الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>منع الحمل في السيدات اللاتي يتناولن عقار لاموكون </strong></p><p dir="RTL">إذا كنتِ سيدة قادرة على الحمل، يجب عليكِ استخدام وسيلة فعَّالة لمنع الحمل مع عقار لاموكون. يشمل هذا ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل البدء بتناوُل عقار لاموكون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء فترة علاجكِ بعقار لاموكون بالكامل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمدة 6 أسابيع بعد توقفكِ عن تناوُل عقار لاموكون</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّثي إلى طبيبكِ حول أكثر وسائل منع الحمل ملاءمةً لك. سيعتمد ذلك على حالتك الفردية. يُفضل استخدام شكلَيْن من أشكال منع الحمل؛ إذ سيقلل ذلك من احتمالية حدوث حمل غير مقصود.&nbsp; <strong>اتصلي بطبيبكِ في أقرب وقت ممكن، إذا كنت تعتقدين أن وسائل منع الحمل الخاصة بكِ قد لا تكون فعالة أو إذا نسيتِ تناول حبوب منع الحمل.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعتبرين سيدة غير قادرة على الحمل إذا كان أيٌّ مما يلي ينطبق عليك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ بفترة ما بعد انقطاع الطمث، أي تبلغين من العمر 50 عامًا على الأقل وكانت آخر دورة شهرية قبل أكثر من عام (إذا توقف الطمث بسبب تلقيكِ علاجًا للسرطان فلا تزال هناك فرصة لأن تصبحي حاملًا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ قد خضعتِ لاستئصال قناتي فالوب وكلا المبيضين جراحيًّا (اسْتِئْصال البُوقِ والمَبِيْض على كلا الجانبين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ قد خضعتِ لاستئصال الرحم جراحيًّا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة عدم عمل المبايض لديكِ (فشل المبايض المبكر والذي أكده طبيب أمراض النساء المتخصص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أحد الحالات النادرة التَّالية منذ الولادة، والتي يستحيل معها حدوث حمل: النمط الجيني XY، أو متلازمة تيرنر، أو عدم تخلُّق الرحم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ طفلة أو مراهقة لم تبلغ سن الحيض بعد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أساليب منع الحمل للرجال الذين يتناولون </strong>عقار لاموكون</p><p dir="RTL">لا تشير الأدلة المتاحة إلى زيادة خطر حدوث تشوهات أو إجهاض إذا تناول الأب مَيكوفينوليت. مع ذلك، لا يمكن استبعاد الخطر تمامًا. كإجراء وقائي، يوصى بأن تستخدم أنت أو زوجتك وسائل موثوقة لمنع الحمل أثناء العلاج ولمدة 90 يومًا بعد التوقف عن تناول عقار لاموكون.</p><p dir="RTL">إذا كنت تخطط لإنجاب طفل، تحدَّث إلى طبيبك حول المخاطر المحتملة والعلاجات البديلة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُل هذا الدَّواء. سيتحدث طبيبكِ معك حول المخاطر في حالة الحمل والبدائل التي يمكنكِ تناوُلها للحيلولة دون رفض العضو المزروع في الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تنوين الحمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انقطعت الدورة الشهرية بالشهر الفائت أو كنتِ تشكين بحدوث ذلك، أو كنتِ تعانين من نزيف حيض غير معتاد، أو إذا كنتِ تشكين في أنكِ حامل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا مارستِ الجماع دون استخدام وسيلة فعَّالة لمنع الحمل.</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء العلاج باستخدام مَيكوفينوليت، يجب عليكِ إبلاغ طبيبكِ فورًا. مع ذلك، استمري بتناوُل عقار لاموكون حتى تذهبي لزيارته/ لزيارتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يُسبب مَيكوفينوليت معدلًا مرتفعًا جدًّا للإجهاض (50٪) والعيوب الخلقية الشديدة (23-27٪) بالأجنة. تشمل العيوب الخلقية التي تم الإبلاغ عنها تشوهات بالأذنين والعينين والوجه (الشفة/ الحنك المشقوق) وتشوهات بنمو الأصابع والقلب والمريء (أنبوب يربط الحلق بالمعدة) والكُلى والجهاز العصبي (على سبيل المثال السِّنْسِنَة المَشْقُوقة (حيث لا يكتمل نمو عظام العمود الفقري جيدًا)). قد يتأثر طفلكِ بواحد أو أكثر من هذه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ سيدة قادرة على الحمل، يجب عليكِ تقديم اختبار حمل سلبي قبل بدء العلاج ويجب عليكِ اتباع النصيحة التي يُقدمها لك طبيبكِ بخصوص منع الحمل. قد يطلب طبيبك أكثر من اختبار واحد؛ للتأكد من أنكِ لستِ حاملًا قبل بدء العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الرَّضاعة الطبيعية</strong></p><p dir="RTL">لا تتناولي عقار لاموكون إذا كنتِ مرضعًا. يرجع ذلك إلى إمكانية مرور كميات قليلة من الدَّواء إلى لبن الأم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لعقار مَيكوفينوليت موفيتيل تأثير معتدل على قدرتك على القيادة أو استخدام أي أدوات أو آلات. إذا كنت تشعر بنعاس أو تنميل أو ارتباك، فتحدث إلى طبيبك أو الممرض(ة) الخاص(ة) بك ولا تمارس القيادة أو تستخدم أي أدوات أو آلات حتى تشعر بتحسن..</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي عقار لاموكون على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) في كل وحدة جرعة، وهذا يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا من كيفية تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الكمية التي يجب أن تتناولها؟</strong></p><p dir="RTL">تعتمد الكمية التي تتناولها على نوع عملية الزرع التي أجريتها. الجرعات المعتادة موضحة أدناه. سيستمر العلاج طالما كنت بحاجة إلى منع جسمك من رفض العضو المزروع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زرع الكُلى</strong></p><p dir="RTL">البالغون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء الجرعة الأولى في غضون 3 أيام من عملية الزرع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة اليومية 4 أقراص (2 جرام من الدواء) يتم تناوُلها في هيئة جرعتين منفصلتين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناوَل قرصين صباحًا وبعد ذلك قرصين مساءً.</p><p dir="RTL">الأطفال (بعُمر عامين إلى 18 عامًا)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تختلف الجرعة التي يتم إعطاؤها حسب حجم الطفل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقرر طبيبك أنسب جرعة بناءً على طول ووزن طفلك (يتم قياس مساحة سطح الجسم بالمتر المربع). تبلغ الجرعة الموصى بها 600 مجم/متر مربع يتم تناولها مرتين يوميًّا.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>الاستخدام في شرائح خاصَّة من المرضى</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">كبار السن</p><p dir="RTL">الجرعة الموصى بها المناسبة لكبار السن تبلغ 1 جرام مرتين في اليوم بالنسبة لمرضى زرع الكُلى و1.5 جرام مرتين في اليوم بالنسبة لمرضى زرع القلب أو الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زرع القلب</strong></p><p dir="RTL">البالغون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء الجرعة الأولى في غضون 5 أيام من عملية الزرع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة اليومية 6 أقراص (3 جرامات من الدواء) يتم تناوُلها في هيئة جرعتين منفصلتين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناوَل 3 أقراص صباحًا وبعد ذلك 3 أقراص مساءً.</p><p dir="RTL">الأطفال</p><p dir="RTL">لا توجد معلومات بخصوص استخدام مَيكوفينوليت موفيتيل في الأطفال الذين خضعوا لعمليات زرع القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زرع الكبد</strong></p><p dir="RTL">البالغون</p><ul><li dir="RTL">سيتم إعطاؤك أول جرعة من مَيكوفينوليت موفيتيل عن طريق الفم بعد 4 أيام على الأقل من عملية الزرع وعندما تكون قادرًا على ابتلاع الأدوية عن طريق الفم.</li><li dir="RTL">تبلغ الجرعة اليومية 6 أقراص (3 جرامات من الدواء) يتم تناوُلها في هيئة جرعتين منفصلتين.</li><li dir="RTL">تناوَل 3 أقراص صباحًا وبعد ذلك 3 أقراص مساءً.</li></ul><p dir="RTL">الأطفال</p><p dir="RTL">لا توجد معلومات حول استخدام عقار لاموكون في الأطفال الذين خضعوا لعمليات زرع الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل الدواء</strong></p><ul><li dir="RTL">قُم ببلع الأقراص كاملةً مع كوب من الماء.</li><li dir="RTL">لا تكسر الأقراص أو تسحقها.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار لاموكون</strong></p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من هذا الدواء، فتحدَّث إلى طبيب أو توجه إلى مستشفى على الفور. افعل ذلك أيضًا إذا تناول شخص آخر الدَّواء بطريق الخطأ. خذ عبوة الدَّواء معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار لاموكون </strong></p><p dir="RTL">إذا أغفلت تناوُل دوائك في أي وقت، فتناوله بمجرد أن تتذكر. استمر بعد ذلك في تناوله في الأوقات المعتادة. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناوُل عقار لاموكون </strong></p><p dir="RTL">لا تتوقف عن تناول هذا الدواء ما لم يخبرك طبيبك بذلك. إذا أوقفت علاجك فقد تزيد من فرصة رفض العضو المزروع لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، استشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدَّث إلى طبيبٍ فورًا إذا لاحظت أيًّا من الآثار الجانبية الخطيرة التَّالية - قد تكون بحاجة إلى علاج طبي عاجل:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك علامة على الإصابة بالعدوى مثل الحُمى أو التهاب الحلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك كدمات أو نزيف غير مُتوقعين.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من طفح جلدي أو تورم في وجهك أو شفتيك أو لسانك أو حلقك، مع صعوبة في التنفس - فقد يكون لديك تفاعل حساسية خطير تجاه الدواء (مثل التَّأق<strong> أو الوذمة الوعائية).</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المشاكل المعتادة</strong></p><p dir="RTL">بعض المشاكل المعتادة هي: الإسهال، وانخفاض تعداد الخلايا البيضاء أو الخلايا الحمراء في الدَّم، والعدوى والقيء. سيقوم طبيبك بإجراء اختبارات دم منتظمة للتَّحقق من أي تغييرات في الآتي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعداد خلايا الدم لديك أو علامات العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون الأطفال أكثر عُرضة للإصابة ببعض الآثار الجانبية أكثر من البالغين. ويشمل ذلك الإِسهال، والعدوى، وانخفاض عدد خلايا الدم البيضاء والحمراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مكافحة العدوى </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يقلل<strong> عقار لاموكون</strong> من دفاعات الجسم لديك. وذلك لمنع جسمك من رفض العضو المزروع. نتيجة لذلك، لن تكون كفاءة جسمك في مكافحة العدوى كالمعتاد. يعني هذا أنك قد تصاب بالعدوى بشكل أكبر من المعتاد. يشمل ذلك حالات العدوى بالمخ والجلد والفم والمعدة والأمعاء والرئتين والجهاز البولي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان الجهاز الليمفاوي والجلد </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يمكن أن يحدث في المرضى الذين يتناولون هذا النوع من الأدوية (كابتات المناعة)، فإنَّ عددًا صغيرًا جدًّا من المرضى الذين يتناولون <strong>عقار لاموكون</strong> قد أصيبوا بسرطان الأنسجة الليمفاوية والجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الآثار غير المرغوبة العامة </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتعرض للإصابة بآثار جانبية عامة تُؤثر على جسمك بالكامل. يشمل ذلك تفاعلات الحساسية الخطيرة (مثل التَّأق أو الوذمة الوعائية)، الحمى، الشعور بالتعب الشديد، صعوبة النوم، آلامًا (مثل آلام المعدة، الصدر، المفاصل أو العضلات)، الصداع، أعراض الإنفلونزا والتورم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتضمن الآثار غير المرغوبة الأخرى ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل بالجلد </strong>مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب، قُرَح البرد، الهربس النطاقي، نمو بالجلد، تساقط الشعر، الطفح الجلدي، الحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل في الجهاز البولي </strong>مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم بالبول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل بالجهاز الهضمي ومشاكل بالفم </strong>مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اللثة وقرح الفم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس أو القولون أو المعدة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الجهاز الهضمي بما في ذلك النزيف،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكبد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال،الإمساك، شعور بالإعياء (غثيان)، عسر الهضم، فقدان الشهية، انتفاخ البطن بالغازات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل الجهاز العصبي </strong>مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بدوخة أو نعاس أو تنميل،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش عضلي، تقلُّصات عضليّة، تشنجات،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق أو الاكتئاب، تغيُّرات بالحالة المزاجية لديك أو بأفكارك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل القلب والأوعية الدموية</strong> مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في ضغط الدَّم، ضربات قلب سريعة، توسُّع الأوعية الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل بالرئة </strong>مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي، التهاب الشعب الهوائية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، السعال، والذي قد يكون ناجمًا عن توسع القَصَبات (حالة تكون فيها الممرات الهوائية بالرئة متوسعة بشكل غير طبيعي) أو التليف الرئوي (تندب الرئة). تحدَّث إلى طبيبك إذا أُصبت بسعال مستمر أو بضيق في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سائل في الرئتين أو داخل الصدر،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الجيوب الأنفية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل أخرى</strong> مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن، مرض النقرس، ارتفاع السكر بالدم، نزيف، كدمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للإبلاغ عن أي(ة) أثر/ آثار جانبي(ة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_16" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:0;margin-top:11.3pt;width:429pt;height:104.9pt;z-index:251656192;
 visibility:visible;mso-position-horizontal:left;
 mso-position-horizontal-relative:margin;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=RTL></span><span dir=RTL></span><b><span
    lang=AR style='font-size:11.0pt;mso-bidi-language:AR'><span dir=RTL></span><span
    dir=RTL></span><span style='mso-spacerun:yes'> </span>معلومات الاتصال
    بالمركز الوطني للتَّيقظ الدوائي بالمملكة العربية السعودية:</span></b><b><span
    dir=LTR style='font-size:11.0pt'><o:p></o:p></span></b></p>
    <p class=MsoPlainText><span style='font-size:11.0pt'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l1 level1 lfo7;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='font-size:11.0pt;mso-bidi-language:AR'>المركز الوطني للتَّيقظ
    الدوائي (</span><span dir=LTR style='font-size:11.0pt'>NPC</span><span
    dir=RTL></span><span dir=RTL></span><span lang=AR style='font-size:11.0pt;
    mso-bidi-language:AR'><span dir=RTL></span><span dir=RTL></span>):</span><span
    dir=LTR style='font-size:11.0pt'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l1 level1 lfo7;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='font-size:11.0pt;mso-bidi-language:AR'>مركز اتصال الهيئة السعودية
    العامة للغذاء والدواء: 19999</span><span dir=LTR style='font-size:11.0pt'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l1 level1 lfo7;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='font-size:11.0pt;mso-bidi-language:AR'>البريد الإلكتروني:</span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:11.0pt;
    color:windowtext;mso-bidi-language:AR;text-decoration:none;text-underline:
    none'> </span><span dir=LTR style='font-size:11.0pt;color:windowtext;
    text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
    dir=LTR style='font-size:11.0pt'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l1 level1 lfo7;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='font-size:11.0pt;mso-bidi-language:AR'>الموقع الإلكتروني </span><span
    dir=LTR style='font-size:11.0pt'>ade.sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1028" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:.3pt;margin-top:144.35pt;
 width:429pt;height:89.25pt;z-index:251658240;visibility:visible;
 mso-position-horizontal-relative:margin;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='margin-top:2.0pt;margin-right:0in;
    margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;text-align:right;
    line-height:12.6pt;text-autospace:none;direction:rtl;unicode-bidi:embed'><b><span
    lang=AR style='font-size:11.0pt;mso-bidi-language:AR'>قسم سلامة المرضى -
    شركة نوفارتس كونسلتينج إيه جي - المملكة العربية السعودية:</span></b><b><span
    dir=LTR style='font-size:11.0pt'><o:p></o:p></span></b></p>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='margin-top:2.0pt;
    margin-right:.25in;margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:12.6pt;mso-list:l4 level1 lfo6;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='mso-bidi-font-size:11.0pt;mso-bidi-language:AR'>الهاتف المجاني:
    8001240078</span><span dir=LTR style='mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:2.0pt;
    margin-right:.25in;margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:12.6pt;mso-list:l4 level1 lfo6;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='mso-bidi-font-size:11.0pt;mso-bidi-language:AR'>الهاتف: 966112658100+</span><span
    dir=LTR style='mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:2.0pt;
    margin-right:.25in;margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:12.6pt;mso-list:l4 level1 lfo6;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='mso-bidi-font-size:11.0pt;mso-bidi-language:AR'>فاكس: 966112658107+</span><span
    dir=LTR style='mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='margin-top:0in;margin-right:
    .25in;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:
    auto;text-align:right;text-indent:-.25in;mso-list:l4 level1 lfo6;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='mso-bidi-font-size:11.0pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR
    style='mso-bidi-font-size:11.0pt;mso-bidi-language:AR'>البريد الإلكتروني: </span><span
    dir=LTR style='mso-bidi-font-size:11.0pt'>adverse.events@novartis.com<o:p></o:p></span></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="146" alt="Text Box:  معلومات الاتصال بالمركز الوطني للتَّيقظ الدوائي بالمملكة العربية السعودية:

o	المركز الوطني للتَّيقظ الدوائي (NPC):
o	مركز اتصال الهيئة السعودية العامة للغذاء والدواء: 19999
o	البريد الإلكتروني: npc.drug@sfda.gov.sa
o	الموقع الإلكتروني ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="125" alt="Text Box: قسم سلامة المرضى - شركة نوفارتس كونسلتينج إيه جي - المملكة العربية السعودية:
o	الهاتف المجاني: 8001240078
o	الهاتف: 966112658100+
o	فاكس: 966112658107+
o	البريد الإلكتروني: adverse.events@novartis.com

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p>&nbsp;</p><ul><br /><li dir="RTL"><strong>دول مجلس التَّعاون الخليجي الأخرى</strong></li><li dir="RTL"><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_15"
      o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
      left:0;text-align:left;margin-left:0;margin-top:3.5pt;width:429pt;
      height:23.25pt;text-indent:0;z-index:251657216;visibility:visible;
      mso-position-horizontal-relative:margin;mso-width-relative:margin;
      mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" fillcolor="window" strokeweight=".5pt">
      <v:path arrowok="t"/>
      <v:textbox>
       <![if !mso]>
       <table cellpadding=0 cellspacing=0 width="100%">
        <tr>
         <td><![endif]>
         <div>
         <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:
         31.5pt;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
         mso-add-space:auto;text-align:right;text-indent:-22.5pt;mso-list:l5 level1 lfo5;
         mso-layout-grid-align:none;text-autospace:none;direction:rtl;
         unicode-bidi:embed'><![if !supportLists]><span style='font-size:12.0pt;
         mso-bidi-font-size:11.0pt'><span style='mso-list:Ignore'>-<span
         style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         </span></span></span><![endif]><span dir=RTL></span><span lang=AR
         style='mso-bidi-font-size:11.0pt;mso-bidi-language:AR'>الرجاء الاتصال
         بالهيئة المختصة ذات الصلة. </span><span dir=LTR style='mso-bidi-font-size:
         11.0pt'><o:p></o:p></span></p>
         <p class=MsoNormal><o:p>&nbsp;</o:p></p>
         <p class=MsoNormal><o:p>&nbsp;</o:p></p>
         </div>
         <![if !mso]></td>
        </tr>
       </table>
       <![endif]></v:textbox>
      <w:wrap anchorx="margin"/>
     </v:shape><![endif]--><img width="578" height="37" alt="Text Box: -	الرجاء الاتصال بالهيئة المختصة ذات الصلة. 


" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image003.gif" />&nbsp;</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة الكرتونية، أو الشريط، أو الملصق بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا يتم التَّخزين في درجة حرارة تتعدى 30 درجة مئوية</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي مَيكوفينوليت موفيتيل. يحتوي كل قرص مغلف على 500 مجم من مَيكوفينوليت موفيتيل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">محتوى القرص الداخلي:</p><p dir="RTL">سليلوز دقيق التبلور، بوفيدون، تلك، ستيرات الماغنسيوم، كروسكارميلوز الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">محتوى الغلاف الخارجي:</p><p dir="RTL">هيبروميلوز، هيدروكسي بروبيل السليلوز، ثاني أكسيد التيتانيوم (E171)، ماكروجول (400)، أكسيد الحديد الأسود (E172)، أكسيد الحديد الأحمر (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار <strong>لاموكون</strong> أقراص مغلَّفة هي عبارة عن أقراص مُغلفة ذات لون أرجواني شاحب، ثنائية التحدُّب، ملساء على كلا الوجهين.</p><p dir="RTL">شرائط من بولي فينيل الكلوريد/ البولي إيثيلين/ البولي فينيل ثنائي الكلوريد/ الألومنيوم</p><p dir="RTL">أحجام العبوات: 50 قرصًا مغلفًا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">هيكسال أيه جي</p><p dir="RTL">إندستري شتراسه 25،</p><p dir="RTL">83607، هولزكيرشن، ألمانيا</p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p dir="RTL">شركة ساندوز برايفيت المحدودة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">مومباي، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2021.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lamucon 500 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500 mg of mycophenolate mofetil. Excipient with known effect:
Each film-coated tablet contains 0.083 mmol (1.90 mg) of sodium.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Lavender coloured, film coated biconvex tablet plain on both the sides.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lamucon is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Lamucon &nbsp;should be initiated and maintained by appropriately qualified transplant specialists.</p><p><u>&nbsp;</u></p><p>Posology</p><p><u>&nbsp;</u></p><p><em>Use in renal transplant</em></p><p><u>&nbsp;</u></p><p>Adults</p><p>Oral Lamucon &nbsp;should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose).</p><p><u>&nbsp;</u></p><p>Paediatric population aged 2 to 18 years</p><p>The recommended dose of mycophenolate mofetil is 600 mg/m<sup>2</sup> administered orally twice daily (up to a maximum of 2 g daily). Lamucon &nbsp;should only be prescribed to patients with a body surface area greater than 1.5 m<sup>2</sup>, at a dose of 1 g twice daily (2 g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction.</p><p>&nbsp;</p><p>Paediatric population &lt;2 years</p><p>There are limited safety and efficacy data in children below the age of 2 years. These are insufficient to make dosage recommendations and therefore use in this age group is not recommended.</p><p><u>&nbsp;</u></p><p><em>Use in cardiac transplant</em></p><p><u>&nbsp;</u></p><p>Adults</p><p>Oral mycophenolate mofetil should be initiated within 5 days following transplantation. The recommended dose in cardiac transplant patients is 1.5 g administered twice daily (3 g daily dose).</p><p>&nbsp;</p><p>Paediatric population</p><p>No data are available for paediatric cardiac transplant patients.</p><p>&nbsp;</p><p><em>Use in hepatic transplant</em></p><p>&nbsp;</p><p>Adults</p><p>Intravenous mycophenolate mofetil should be administered for the first 4 days following hepatic transplant, with oral mycophenolate mofetil initiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose).</p><p>&nbsp;</p><p>Paediatric population</p><p>No data are available for paediatric hepatic transplant patients.</p><p>&nbsp;</p><p><em>Use in special populations</em></p><p>&nbsp;</p><p>Elderly</p><p>The recommended dose of 1 g administered twice a day for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In renal transplant patients with severe chronic renal impairment (glomerular filtration rate &lt;25 mL/min/1.73 m<sup>2</sup>), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided. These patients should also be carefully observed.</p><p>No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively (see section 5.2). No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p><u>&nbsp;</u></p><p><em>Severe hepatic impairment </em></p><p>No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.</p><p><u>&nbsp;</u></p><p><em>Treatment during rejection episodes </em></p><p>Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Lamucon &nbsp;is not required. There is no basis for Lamucon &nbsp;dose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant rejection.</p><p>&nbsp;</p><p>Paediatric population</p><p>No data are available for treatment of first or refractory rejection in paediatric transplant patients</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral administration</p><p><em>&nbsp;</em></p><p><em>Precautions to be taken before handling or administering the medicinal product.</em></p><p>Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Lamucon &nbsp;tablets should not be crushed.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                        Mycophenolate mofetil should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1. Hypersensitivity reactions to mycophenolate mofetil have been observed (see section 4.8).



·         Mycophenolate mofetil should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6).



·         Mycophenolate mofetil treatment should not be initiated in women of childbearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6).



·         Mycophenolate mofetil should not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6).



·         Mycophenolate mofetil should not be given to women who are breastfeeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neoplasms</u></p><p>Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As general advice to minimise the risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p>&nbsp;</p><p><u>Infections</u></p><p>Patients treated with immunosuppressants, including mycophenolate mofetil, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). Such infections include latent viral reactivation, such as hepatitis B or hepatitis C reactivation and infections caused by polyomaviruses (BK virus associated nephropathy, JC virus associated progressive multifocal leukoencephalopathy PML). Cases of hepatitis due to reactivation of hepatitis B or hepatitis C have been reported in carrier patients treated with immunosuppressants. These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms. Mycophenolic acid has a cytostatic effect on B- and T-lymphocytes, therefore an increased severity of COVID-19 may occur. Dose reduction or discontinuation of Lamucon &nbsp;should be considered for patients in cases of clinically significant COVID-19.</p><p>&nbsp;</p><p>There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving mycophenolate mofetil in combination with other immunosuppressants. In some of these cases switching mycophenolate mofetil to an alternative immunosuppressant resulted in serum IgG levels returning to normal. Patients on mycophenolate mofetil who develop recurrent infections should have their serum immunoglobulins measured. In cases of sustained, clinically relevant hypogammaglobulinaemia, appropriate clinical action should be considered taking into account the potent cytostatic effects that mycophenolic acid has on T- and B-lymphocytes.</p><p>&nbsp;</p><p>There have been published reports of bronchiectasis in adults and children who received mycophenolate mofetil in combination with other immunosuppressants. In some of these cases switching mycophenolate mofetil to another immunosuppressant resulted in improvement in respiratory symptoms. The risk of bronchiectasis may be linked to hypogammaglobulinaemia or to a direct effect on the lung. There have also been isolated reports of interstitial lung disease and pulmonary fibrosis, some of which were fatal (see section 4.8). It is recommended that patients who develop persistent pulmonary symptoms, such as cough and dyspnoea, are investigated.</p><p>&nbsp;</p><p><u>Blood and immune system</u></p><p>Patients receiving mycophenolate mofetil should be monitored for neutropenia, which may be related to mycophenolate mofetil itself, concomitant medications, viral infections, or some combination of these causes. Patients taking mycophenolate mofetil should have complete blood counts weekly during the first month, twice monthly for the second and third months of treatment, then monthly through the first year. If neutropenia develops (absolute neutrophil count &lt;1.3 x 10<sup>3</sup>/&micro;l), it may be appropriate to interrupt or discontinue mycophenolate mofetil.</p><p>&nbsp;</p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressants. The mechanism for mycophenolate mofetil induced PRCA is unknown. PRCA may resolve with dose reduction or cessation of mycophenolate mofetil therapy. Changes to mycophenolate mofetil therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8).</p><p>&nbsp;</p><p>Patients receiving mycophenolate mofetil should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow failure.</p><p>&nbsp;</p><p>Patients should be advised that during treatment with mycophenolate mofetil, vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section 4.5). Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination.</p><p>&nbsp;</p><p><u>Gastrointestinal</u></p><p>Mycophenolate mofetil has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation, mycophenolate mofetil should be administered with caution in patients with active serious digestive system disease.</p><p>&nbsp;</p><p>Mycophenolate mofetil is an IMPDH (inosine monophosphate dehydrogenase) inhibitor. Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p><p>&nbsp;</p><p><u>Interactions</u></p><p>Caution should be exercised when switching combination therapy from regimens containing immunosuppressants, which interfere with MPA enterohepatic recirculation e.g. ciclosporin to others devoid of this effect e.g. tacrolimus, sirolimus, belatacept, or vice versa, as this might result in changes of MPA exposure. Medicinal products which interfere with MPA&rsquo;s enterohepatic cycle (e.g. cholestyramine, antibiotics) should be used with caution due to their potential to reduce the plasma level and efficacy of mycophenolate mofetil (see also section 4.5). Therapeutic drug monitoring of MPA may be appropriate when switching combination therapy (e.g. from ciclosporin to tacrolimus or vice versa) or to ensure adequate immunosuppression in patients with high immunological risk (e.g. risk of rejection, treatment with antibiotics, addition or removal of an interacting medication).</p><p>&nbsp;</p><p>It is recommended that mycophenolate mofetil should not be administered concomitantly with azathioprine because such concomitant administration has not been studied.</p><p>&nbsp;</p><p>The risk/benefit ratio of mycophenolate mofetil in combination with sirolimus has not been established (see also section 4.5).</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Elderly patients may be at an increased risk of adverse events such as certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared with younger individuals (see section 4.8).</p><p>&nbsp;</p><p><u>Teratogenic effects</u></p><p>Mycophenolate is a powerful human teratogen. Spontaneous abortion (rate of 45 % to 49 %) and congenital malformations (estimated rate of 23 % to 27 %) have been reported following mycophenolate mofetil exposure during pregnancy. Therefore mycophenolate mofetil is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection. Female patients of childbearing potential should be made aware of the risks and follow the recommendations provided in section 4.6. (e.g. contraceptive methods, pregnancy testing) prior to, during, and after therapy with mycophenolate mofetil. Physicians should ensure that women taking mycophenolate understand the risk of harm to the baby, the need for effective contraception, and the need to immediately consult their physician if there is a possibility of pregnancy.</p><p><u>&nbsp;</u></p><p><u>Contraception (see section 4.6)</u></p><p>Because of robust clinical evidence showing a high risk of abortion and congenital malformations when mycophenolate mofetil is used in pregnancy every effort to avoid pregnancy during treatment should be taken. Therefore women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting mycophenolate mofetil therapy, during therapy, and for six weeks after stopping the therapy; unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred to minimise the potential for contraceptive failure and unintended pregnancy.</p><p>&nbsp;</p><p>For contraception advice for men see section 4.6.</p><p>&nbsp;</p><p><u>Educational materials</u></p><p>In order to assist patients in avoiding foetal exposure to mycophenolate and to provide additional important safety information, the Marketing Authorisation Holder will provide educational materials to healthcare professionals. The educational materials will reinforce the warnings about the teratogenicity of mycophenolate, provide advice on contraception before therapy is started and guidance on the need for pregnancy testing. Full patient information about the teratogenic risk and the pregnancy prevention measures should be given by the physician to women of childbearing potential and, as appropriate, to male patients.</p><p>&nbsp;</p><p>Additional precautions</p><p>Patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate. Men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate.</p><p>&nbsp;</p><p>Lamucon &nbsp;contains sodium</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Aciclovir</u></p><p>Higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone. The changes in MPAG (the phenolic glucuronide of MPA) pharmacokinetics h(MPAG increased by 8%) were minimal and are not considered clinically significant. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are aciclovir concentrations, the potential exists for mycophenolate mofetil and aciclovir, or its prodrugs, e.g. valaciclovir, to compete for tubular secretion and further increases in concentrations of both substances may occur.</p><p>&nbsp;</p><p><u>Antacids and proton pump inhibitors (PPIs)</u></p><p>Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs.</p><p>&nbsp;</p><p><u>Medicinal products that interfere with enterohepatic recirculation (e.g. cholestyramine, ciclosporin A,</u></p><p><u>antibiotics)</u></p><p>Caution should be used with medicinal products that interfere with enterohepatic recirculation because of their potential to reduce the efficacy of mycophenolate mofetil.</p><p>&nbsp;</p><p><u>Cholestyramine</u></p><p>Following single dose administration of 1.5 g of mycophenolate mofetil to normal healthy subjects pre-treated with 4 g TID of cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4 and section 5.2). Caution should be used during concomitant administration because of the potential to reduce efficacy of mycophenolate mofetil.</p><p>&nbsp;</p><p><u>Ciclosporin A</u></p><p>Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil. In contrast, if concomitant ciclosporin treatment is stopped, an increase in MPA AUC of around 30% should be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30‑50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to one of the immunosuppressants which does not interfere with MPA&acute;s enterohepatic cycle.</p><p>&nbsp;</p><p>Antibiotics eliminating &beta;-glucuronidase-producing bacteria in the intestine (e.g. aminoglycoside, cephalosporin, fluoroquinolone, and penicillin classes of antibiotics) may interfere with MPAG/MPA enterohepatic recirculation thus leading to reduced systemic MPA exposure. Information concerning the following antibiotics is available:<u> </u></p><p><u>&nbsp;</u></p><p><u>Ciprofloxacin or amoxicillin plus clavulanic acid:</u></p><p>Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal transplant recipients in the days immediately following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to cease within a few days of antibiotic discontinuation. The change in predose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</p><p>&nbsp;</p><p><u>Norfloxacin and metronidazole</u></p><p>In healthy volunteers, no significant interaction was observed when mycophenolate mofetil was concomitantly administered with norfloxacin or metronidazole separately. However, norfloxacin and metronidazole combined reduced the MPA exposure by approximately 30% following a single dose of mycophenolate mofetil.</p><p>&nbsp;</p><p><u>Trimethoprim/sulfamethoxazole</u></p><p>No effect on the bioavailability of MPA was observed.</p><p>&nbsp;</p><p>Medicinal products that affect glucuronidation (e.g. isavuconazole, telmisartan)</p><p>Concomitant administration of drugs affecting glucuronidation of MPA may change MPA exposure. Caution is therefore recommended when administering these drugs concomitantly with mycophenolate mofeti.</p><p>&nbsp;</p><p>Isavuconazole</p><p>An increase of MPA AUC0-&infin; by 35% was observed with concomitant administration of isavuconazole.</p><p>&nbsp;</p><p><em>Telmisartan</em></p><p>Concomitant administration of telmisartan and mycophenolate mofetil resulted in an approximately 30% decrease of MPA concentrations. Telmisartan changes MPA&rsquo;s elimination by enhancing PPAR&nbsp;gamma (peroxisome proliferator-activated receptor&nbsp;gamma) expression, which in turn results in an enhanced UGT1A9 expression and activity. When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between mycophenolate mofetil patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic drug-drug interaction were seen.</p><p>&nbsp;</p><p><u>Ganciclovir</u></p><p>Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics is anticipated and mycophenolate mofetil dose adjustment is not required. In patients with renal impairment in whom mycophenolate mofetil and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered the dose recommendations for ganciclovir should be observed and patients should be monitored carefully.</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by co-administration of mycophenolate mofetil (see also section 5.2).</p><p>&nbsp;</p><p><u>Rifampicin</u></p><p>In patients not also taking ciclosporin, concomitant administration of mycophenolate mofetil and rifampicin resulted in a decrease in MPA exposure (AUC<sub>0-12h</sub>) of 18% to 70%. It is recommended to monitor MPA exposure levels and to adjust mycophenolate mofetil doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.</p><p>&nbsp;</p><p><u>Sevelamer</u></p><p>Decrease in MPA C<sub>max</sub> and AUC (0-12h) by 30% and 25%, respectively, were observed when mycophenolate mofetil was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). It is recommended, however, to administer mycophenolate mofetil at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption of MPA. There are no data on mycophenolate mofetil with phosphate binders other than sevelamer.</p><p>&nbsp;</p><p><u>Tacrolimus</u></p><p>In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and C<sub>max</sub> of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co-administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5&nbsp;g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by mycophenolate mofetil (see also section 4.4).</p><p>&nbsp;</p><p><u>Live vaccines</u></p><p>Live vaccines should not be given to patients with an impaired immune response. The antibody response to other vaccines may be diminished (see also section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p><u>Potential interaction </u></p><p>Co-administration of probenecid with mycophenolate mofetil in monkeys raises plasma AUC of MPAG by 3-fold. Thus, other substances known to undergo renal tubular secretion may compete with MPAG and thereby raise plasma concentrations of MPAG or the other substance undergoing tubular secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>Pregnancy whilst taking mycophenolate must be avoided. Therefore women of childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Lamucon &nbsp;-therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>Mycophenolate mofetil is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection. Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy (see section 4.3).</p><p>&nbsp;</p><p>Female patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counselled regarding pregnancy prevention, and planning.</p><p>&nbsp;</p><p>Before starting mycophenolate mofetil treatment, women of childbearing potential should have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL in order to exclude unintended exposure of the embryo to mycophenolate. It is recommended that the second test should be performed 8&ndash;10 days after the first test. For transplants from deceased donors, if it is not possible to perform two tests 8-10 days apart before treatment starts (because of the timing of transplant organ availability), a pregnancy test must be performed immediately before starting treatment and a further test performed 8-10 days later. Pregnancy tests should be repeated as clinically required (e.g. after any gap in contraception is reported. Results of all pregnancy tests should be discussed with the patient. Patients should be instructed to consult their physician immediately should pregnancy occur.</p><p>&nbsp;</p><p>Mycophenolate is a powerful human teratogen, with an increased risk of spontaneous abortions and congenital malformations in case of exposure during pregnancy;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on literature reports, malformations occurred in 23 to 27% of live births in women exposed to mycophenolate mofetil during pregnancy (compared to 2 to 3 % of live births in the overall population and approximately 4 to 5% of live births in solid organ transplant recipients treated with immunosuppressants other than mycophenolate mofetil).</p><p>&nbsp;</p><p>Congenital malformations, including reports of multiple malformations, have been observed post-marketing in children of patients exposed to mycophenolate mofetil during pregnancy in combination with other immunosuppressants. The following malformations were most frequently reported:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities of the ear (e.g. abnormally formed or absent external ear), external auditory canal atresia (middle ear);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities of the eye (e.g. coloboma);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital heart disease such as atrial and ventricular septal defects;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malformations of the fingers (e.g. polydactyly, syndactyly);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tracheo-oesophageal malformations (e.g. oesophageal atresia);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous system malformations such as spina bifida;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal abnormalities.</p><p>&nbsp;</p><p>In addition there have been isolated reports of the following malformations:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microphthalmia;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital choroid plexus cyst;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Septum pellucidum agenesis;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Olfactory nerve agenesis.</p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Mycophenolate mofetil has been shown to be excreted in the milk of lactating rats. It is not known whether this substance is excreted in human milk. Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, mycophenolate mofetil is contraindicated in nursing mothers (see section 4.3).</p><p>&nbsp;</p><p><u>Men</u></p><p>Limited clinical evidence does not indicate an increased risk of malformations or miscarriage following paternal exposure to mycophenolate mofetil.</p><p>MPA is a powerful teratogen. It is not known if MPA is present in semen. Calculations based on animal data show that the maximum amount of MPA that could potentially be transferred to woman is so low that it would be unlikely to have an effect. Mycophenolate has been shown to be genotoxic in animal studies at concentrations exceeding the human therapeutic exposures only by small margins, such that the risk of genotoxic effects on sperm cells cannot completely be excluded.</p><p>Therefore, the following precautionary measures are recommended: sexually active male patients or their female partners are recommended to use reliable contraception during treatment of the male patient and for at least 90 days after cessation of mycophenolate mofetil. Male patients of reproductive potential should be made aware of and discuss with a qualified health-care professional the potential risks of fathering a child.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mycophenolate mofetil has a moderate influence on the ability to drive and use machines.</p><p>Mycophenolate mofetil may cause somnolence, confusion, dizziness, tremor or hypotension, and therefore patients are advised to use caution when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of safety profile</em></p><p>An estimated total of 1557 patients received mycophenolate mofetil during five clinical trials in the prevention of acute organ rejection. Of these, 991 were included in the three renal studies, 277 were included in one hepatic study, and 289 were included in one cardiac study. Azathioprine was the comparator used in the hepatic and cardiac studies and in two of the renal studies whilst the other renal study was placebo-controlled. Patients in all study arms also received ciclosporin and corticosteroids. The types of adverse reactions reported during post-marketing with mycophenolate mofetil are similar to those seen in the controlled renal, cardiac and hepatic transplant studies.</p><p>Diarrhoea, leucopenia, sepsis and vomiting were among the most common and/or serious adverse drug reactions associated with the administration of mycophenolate mofetil in combination with ciclosporin and corticosteroids. There is also evidence of a higher frequency of certain types of infections (see section 4.4).</p><p><u>&nbsp;</u></p><p><em>Tabulated list of adverse reactions</em></p><p>The adverse drug reactions (ADRs) from clinical trials and post-marketing experience are listed in Table 1, by MedDRA system organ class (SOC) along with their frequencies. The corresponding frequency category for each adverse drug reaction is based on the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). Due to the large differences observed in the frequency of certain ADRs across the different transplant indications, the frequency is presented separately for renal, hepatic and cardiac transplant patients.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse drug reaction (MedDRA)</strong></p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Renal transplant</strong></p><p><strong>n = 991</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Hepatic transplant</strong></p><p><strong>n = 277</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Cardiac transplant</strong></p><p><strong>n = 289</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Frequency</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bacterial infections</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Fungal infections</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Protozoal infections</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Viral infections</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Benign neoplasm of skin</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Lymphoma</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Lymphoproliferative disorder</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasm</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin cancer</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Aplasia pure red cell</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow failure</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Ecchymosis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Leukocytosis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pseudolymphoma</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acidosis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperlipidaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphataemia</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Gout</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Thinking abnormal</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Convulsion</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocele</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Venous thrombosis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bronchiectasis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial lung disease</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pleural effusion</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary fibrosis</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distension</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Colitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Oesophagitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Eructation</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal ulcer</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Ileus</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Mouth ulceration</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypersenstivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypogammaglobulinaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very Rare</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase</p><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood lactate dehydrogenase</p><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hyperbilirubinaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acne</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin hypertrophy</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Renal impairment</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hernia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p><em>De novo</em> purine synthesis inhibitors associated acute inflammatory syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>Note: 991 (2&nbsp;g&nbsp;/&nbsp;3 g mycophenolate mofetil daily), 289 (3&nbsp;g mycophenolate mofetil daily) and 277 (2&nbsp;g IV&nbsp;/&nbsp;3 g oral mycophenolate mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.</p><p>&nbsp;</p><p><em>Description of selected adverse reactions</em><u> </u></p><p>Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3&nbsp;years.</p><p>&nbsp;</p><p><em>Infections</em></p><p>All patients treated with immunosuppressants are at increased risk of bacterial, viral and fungal infections (some of which may lead to a fatal outcome), including those caused by opportunistic agents and latent viral reactivation. The risk increases with total immunosuppressive load (see section&nbsp;4.4). The most serious infections were sepsis, peritonitis, meningitis, endocarditis, tuberculosis and atypical mycobacterial infection. The most common opportunistic infections in patients receiving mycophenolate mofetil (2&nbsp;g or 3&nbsp;g daily) with other immunosuppressants in controlled clinical trials in renal, cardiac and hepatic transplant patients followed for at least 1&nbsp;year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex. The proportion of patients with CMV viraemia/syndrome was 13.5%. &nbsp;Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including mycophenolate mofetil.</p><p>&nbsp;</p><p><em>Blood and lymphatic system disorders</em></p><p>Cytopenias, including leukopenia, anaemia, thrombocytopenia and pancytopenia, are known risks associated with mycophenolate mofetil and may lead or contribute to the occurrence of infections and haemorrhages (see section&nbsp;4.4). Agranulocytosis &nbsp;and neutropenia have been reported; therefore, regular monitoring of patients taking mycophenolate mofetil is advised (see section 4.4). There have been reports of aplastic anaemia and bone marrow failure in patients treated with mycophenolate mofetil, some of which have been fatal.</p><p>&nbsp;</p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil (see section 4.4).</p><p>&nbsp;</p><p>Isolated cases of abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, have been observed in patients treated with mycophenolate mofetil. These changes are not associated with impaired neutrophil function. These changes may suggest a &lsquo;left shift&rsquo; in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive mycophenolate mofetil.</p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>The most serious gastrointestinal disorders were ulceration and haemorrhage which are known risks associated with mycophenolate mofetil. Mouth, oesophageal, gastric, duodenal, and intestinal ulcers often complicated by haemorrhage, as well as haematemesis, maelena, and haemorrhagic forms of gastritis and colitis were commonly reported during the pivotal clinical trials. The most common gastrointestinal disorders, however, were diarrhoea, nausea and vomiting. Endoscopic investigation of patients with mycophenolate mofetil-related diarrhoea have revealed isolated cases of intestinal villous atrophy (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><em>Hypersensitivity</em></p><p>Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Pregnancy, puerperium and perinatal conditions</em></p><p>Cases of spontaneous abortion have been reported in patients exposed to mycophenolate mofetil, mainly in the first trimester, see section 4.6.</p><p>&nbsp;</p><p><em>Congenital disorders</em></p><p>Congenital malformations have been observed post-marketing in children of patients exposed to mycophenolate mofetil in combination with other immunosuppressants, see section 4.6.</p><p>&nbsp;</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with mycophenolate mofetil in combination with other immunosuppressants, some of which have been fatal. There have also been reports of bronchiectasis in children and adults.</p><p>&nbsp;</p><p><em>Immune system disorders</em></p><p>Hypogammaglobulinaemia has been reported in patients receiving mycophenolate mofetil in combination with other immunosuppressants.</p><p>&nbsp;</p><p><em>General disorders and administration site conditions</em></p><p>Oedema, including peripheral, face and scrotal oedema, was reported very commonly during the pivotal trials. Musculoskeletal pain such as myalgia, and neck and back pain were also very commonly reported.</p><p>&nbsp;</p><p><em>De novo</em> purine synthesis inhibitors-associated acute inflammatory syndrome has been described from post-marketing experience as a paradoxical proinflammatory reaction associated with mycophenolate mofetil and mycophenolic acid, characterised by fever, arthralgia, arthritis, muscle pain and elevated inflammatory markers. Literature case reports showed rapid improvement following discontinuation of the medicinal product.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Paediatric population </em></p><p>The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m<sup>2</sup> mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g mycophenolate mofetil twice daily. However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.</p><p>&nbsp;</p><p><em>Elderly </em></p><p>Elderly patients (&ge;65 years) may generally be at increased risk of adverse reactions due to immunosuppression. Elderly patients receiving mycophenolate mofetil as part of a combination immunosuppressive regimen may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_7" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:0;margin-top:-23.75pt;
 width:429pt;height:104.9pt;z-index:251657728;visibility:visible;
 mso-position-horizontal-relative:margin;mso-width-relative:margin;
 mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQAms5vYYQIAAMwEAAAOAAAAZHJzL2Uyb0RvYy54bWysVMtu2zAQvBfoPxC8N/IrLyNy4CZwUcBI
AiRFzjRFxUIoLkvSltyv75CSHTfpqagPNMldzu7Ozurquq012yrnKzI5H54MOFNGUlGZl5z/eFp8
ueDMB2EKocmonO+U59ezz5+uGjtVI1qTLpRjADF+2ticr0Ow0yzzcq1q4U/IKgNjSa4WAUf3khVO
NECvdTYaDM6yhlxhHUnlPW5vOyOfJfyyVDLcl6VXgemcI7eQVpfWVVyz2ZWYvjhh15Xs0xD/kEUt
KoOgB6hbEQTbuOoDVF1JR57KcCKpzqgsK6lSDahmOHhXzeNaWJVqATneHmjy/w9W3m0fHKuKnJ9z
ZkSNFj2pNrCv1LLzyE5j/RROjxZuocU1upwq9XZJ8tXDJTvy6R54eEc22tLV8R91MjxEA3YH0mMU
icvTyeRiPIBJwjYcj0ejcWpL9vbcOh++KapZ3OTcoaspBbFd+hATENO9S4zmSVfFotI6HXb+Rju2
FRAAdFNQw5kWPuAy54v0i2UC4o9n2rAm52fj00FX7DFkjHXAXGkhXz8iAE+bnpqOjUhSaFdtz+mK
ih0oddRJ0lu5qIC7RGoPwkGDYARzFe6xlJqQDPU7ztbkfv3tPvpDGrBy1kDTOfc/N8IpVPzdQDSX
w8kkDkE6TE7PRzi4Y8vq2GI29Q2BtSEm2Mq0jf5B77elo/oZ4zePUWESRiJ2zsN+exO6ScP4SjWf
JyfI3oqwNI9W7pUU+Xxqn4WzfYMDtHFHe/WL6bs+d76xuYbmm0BllUQQCe5Y7XnHyKTG9uMdZ/L4
nLzePkKz3wAAAP//AwBQSwMEFAAGAAgAAAAhAEQtqJXfAAAACAEAAA8AAABkcnMvZG93bnJldi54
bWxMj8FOwzAQRO9I/IO1SNxah5aUEOJUpRKCnhBtJcTNibdJlHgdxW4a/p7lBMedGc2+ydaT7cSI
g28cKbibRyCQSmcaqhQcDy+zBIQPmozuHKGCb/Swzq+vMp0ad6EPHPehElxCPtUK6hD6VEpf1mi1
n7seib2TG6wOfA6VNIO+cLnt5CKKVtLqhvhDrXvc1li2+7NVsHnfFW++XJ5G027x9fO5bx+/YqVu
b6bNE4iAU/gLwy8+o0POTIU7k/GiU8BDgoLZ/UMMgu0kTlgpOLdaLEHmmfw/IP8BAAD//wMAUEsB
Ai0AFAAGAAgAAAAhALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVz
XS54bWxQSwECLQAUAAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAAAAAAAAAvAQAAX3JlbHMv
LnJlbHNQSwECLQAUAAYACAAAACEAJrOb2GECAADMBAAADgAAAAAAAAAAAAAAAAAuAgAAZHJzL2Uy
b0RvYy54bWxQSwECLQAUAAYACAAAACEARC2old8AAAAIAQAADwAAAAAAAAAAAAAAAAC7BAAAZHJz
L2Rvd25yZXYueG1sUEsFBgAAAAAEAAQA8wAAAMcFAAAAAA==
" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-bidi-font-weight:bold'><span style='mso-spacerun:yes'> </span>NPC
    contact information Saudi Arabia:<o:p></o:p></span></p>
    <p class=MsoPlainText><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
    mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";mso-bidi-font-weight:
    bold'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;mso-bidi-font-weight:bold'>The
    National Pharmacovigilance Centre (NPC):<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";mso-bidi-font-weight:
    bold'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;mso-bidi-font-weight:bold'>SFDA
    Call Center: 19999<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";mso-bidi-font-weight:
    bold'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;mso-bidi-font-weight:bold'>E-mail:
    <a href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
    text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";mso-bidi-font-weight:
    bold'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;mso-bidi-font-weight:bold'>Website
    ade.sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoNormal><span style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="576" height="144" alt="Text Box:  NPC contact information Saudi Arabia:

o	The National Pharmacovigilance Centre (NPC):
o	SFDA Call Center: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience. In many of these cases, no adverse events were reported. In those overdose cases in which adverse events were reported, the events fall within the known safety profile of the medicinal product.</p><p>&nbsp;</p><p>It is expected that an overdose of mycophenolate mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). If neutropenia develops, dosing with mycophenolate mofetil should be interrupted or the dose reduced (see section 4.4).</p><p><u>&nbsp;</u></p><p>Haemodialysis would not be expected to remove clinically significant amounts of MPA or MPAG. Bile acid sequestrants, such as cholestyramine, can remove MPA by decreasing the enterohepatic recirculation of the drug (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immunosuppressive agents ATC code L04AA06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the <em>de novo</em> pathway of guanosine nucleotide synthesis without incorporation into DNA.</p><p>Because T- and B-lymphocytes are critically dependent for their proliferation on <em>de novo</em> synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration, mycophenolate mofetil undergoes rapid and extensive absorption and complete presystemic metabolism to the active metabolite, MPA. As evidenced by suppression of acute rejection following renal transplantation, the immunosuppressant activity of mycophenolate mofetil is correlated with MPA concentration. The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5 g BID to renal transplant patients. However, MPA C<sub>max</sub> was decreased by 40% in the presence of food.</p><p>Mycophenolate mofetil is not measurable systemically in plasma following oral administration.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6 &ndash; 12 hours post-dose. A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of cholestyramine (4 g TID), indicating that there is a significant amount of enterohepatic recirculation.</p><p>MPA at clinically relevant concentrations is 97% bound to plasma albumin.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>MPA is metabolised principally by glucuronyl transferase (isoform UGT1A9) to form the inactive phenolic glucuronide of MPA (MPAG). <em>In vivo</em>, MPAG is converted back to free MPA via enterohepatic recirculation. A minor acylglucuronide (AcMPAG) is also formed. AcMPAG is pharmacologically active and is suspected to be responsible for some of MMF&acute;s side effects (diarrhoea, leukopenia).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>A negligible amount of substance is excreted as MPA (&lt; 1% of the dose) in the urine. Oral administration of radiolabelled mycophenolate mofetil results in complete recovery of the administered dose; with 93% of the administered dose recovered in the urine and 6% recovered in the faeces. Most (about 87%) of the administered dose is excreted in the urine as MPAG.</p><p>&nbsp;</p><p>At clinically encountered concentrations, MPA and MPAG are not removed by haemodialysis. However, at high MPAG plasma concentrations (&gt; 100 &micro;g/mL), small amounts of MPAG are removed. By interfering with enterohepatic recirculation of the drug, bile acid sequestrants such as cholestyramine, reduce MPA AUC (see section 4.9).</p><p>&nbsp;</p><p>MPA&rsquo;s disposition depends on several transporters. Organic anion‑transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA&rsquo;s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides&rsquo; biliary excretion. Multidrug resistance protein 1 (MDR1) is also able to transport MPA, but its contribution seems to be confined to the absorption process. In the kidney MPA and its metabolites potently interact with renal organic anion transporters.</p><p>&nbsp;</p><p>In the early post-transplant period (&lt; 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and C<sub>max</sub> approximately 40% lower compared to the late post-transplant period (3 &ndash; 6 months post-transplant).</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate &lt;25 mL/min/1.73 m<sup>2</sup>) were 28&ndash;75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment. The mean single dose MPAG AUC was 3&ndash;6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG. Multiple dosing of mycophenolate mofetil in patients with severe chronic renal impairment has not been studied. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p>&nbsp;</p><p><em>Delayed renal graft function</em></p><p>In patients with delayed renal graft function post-transplant, mean MPA AUC<sub>(0&ndash;12h)</sub> was comparable to that seen in post-transplant patients without delayed graft function. Mean plasma MPAG AUC<sub>(0-12h)</sub> was 2&ndash;3-fold higher than in post-transplant patients without delayed graft function. There may be a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. Dose adjustment of mycophenolate mofetil does not appear to be necessary.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In volunteers with alcoholic cirrhosis, hepatic MPA glucuronidation processes were relatively unaffected by hepatic parenchymal disease. Effects of hepatic disease on this process probably depend on the particular disease. However, hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18 years) given 600 mg/m<sup>2</sup> mycophenolate mofetil orally twice daily. This dose achieved MPA AUC values similar to those seen in adult renal transplant patients receiving mycophenolate mofetil at a dose of 1&nbsp;g BID in the early and late post-transplant period. MPA AUC values across age groups were similar in the early and late post-transplant period.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>The pharmacokinetics of mycophenolate mofetil and its metabolites have not been found to be altered in the elderly (&ge;65 years) when compared to younger transplant patients.</p><p>&nbsp;</p><p><em>Patients taking oral contraceptives</em></p><p>A study of the co-administration of mycophenolate mofetil (1 g bid) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.15 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of mycophenolate on the ovulation suppressing action of the oral contraceptives. Serum levels of LH, FSH and progesterone were not significantly affected. The pharmacokinetics of oral contraceptives were unaffected by co-administration of mycophenolate mofeti (see also section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In experimental models, mycophenolate mofetil was not tumourigenic. The highest dose tested in the animal carcinogenicity studies resulted in approximately 2&ndash;3 times the systemic exposure (AUC or C<sub>max</sub>) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3 &ndash;2 times the systemic exposure (AUC or C<sub>max</sub>) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day.</p><p>&nbsp;</p><p>Two genotoxicity assays (<em>in vitro</em> mouse lymphoma assay and <em>in vivo</em> mouse bone marrow micronucleus test) showed a potential of mycophenolate mofetil to cause chromosomal aberrations. These effects can be related to the pharmacodynamic mode of action, i.e. inhibition of nucleotide synthesis in sensitive cells. Other <em>in vitro</em> tests for detection of gene mutation did not demonstrate genotoxic activity.</p><p>&nbsp;</p><p>Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20 mg/kg/day.</p><p>The systemic exposure at this dose represents 2&ndash;3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3&ndash;2 times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients. In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.</p><p>&nbsp;</p><p>In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity. The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients (see section 4.6).</p><p>&nbsp;</p><p>The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with mycophenolate mofetil in the rat, mouse, dog and monkey. These effects occurred at systemic exposure levels that are equivalent to or less than the clinical exposure at the recommended dose of 2 g/day for renal transplant recipients. Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose. Gastrointestinal and renal effects consistent with dehydration were also observed in the monkey at the highest dose (systemic exposure levels equivalent to or greater than clinical exposure). The nonclinical toxicity profile of mycophenolate mofetil appears to be consistent with adverse events observed in human clinical trials which now provide safety data of more relevance to the patient population (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Core content:</em></p><p>Cellulose microcrystalline</p><p>Povidone</p><p>Talc</p><p>Magnesium stearate</p><p>Croscarmellose sodium</p><p>&nbsp;</p><p><em>Coating content:</em></p><p>Hypromellose</p><p>Hydroxypropylcellulose</p><p>Titanium dioxide (E 171)</p><p>Macrogol(400)</p><p>Iron Oxide Black (E 172)</p><p>Iron Oxide Red (E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30˚C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC/Alu blister</p><p>Pack sizes: 50 film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, tablets should not be crushed.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HEXAL AG
Industriestrasse 25
83607, Holzkirchen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23.10.2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>